Skip to main content
Premium Trial:

Request an Annual Quote

VC Firm Summit to Buy Minority Stake in Genomic Tool Shop Fermentas

NEW YORK (GenomeWeb News) — Venture capital group Summit Partners plans to make “a significant minority investment” in genomics and proteomics technology provider Fermentas International, the company said today.
 
Fermentas did not disclose the amount of the investment -- it said it “signed a definitive agreement to accept” Summit’s offer -- but said it plans to use the funds for organic growth and for new partnerships and acquisitions.
 
Fermentas was founded in the mid-1970s as part of the Soviet Union-funded Institute of Applied Enzymology and became an independent entity in 1995.
 
Although the company retains its offices in Vilnius, Lithuania, it is headquartered in Burlington, Ontario.
 
As part of the investment, Thomas Jennings, a principal with Summit Partners, will join the Fermentas board.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.